Eli Lilly and Company (NYSE:LLY) Given New $1,200.00 Price Target at Wells Fargo & Company
Wells Fargo & Company raised Eli Lilly's price target from $1,100 to $1,200, maintaining an "overweight" rating, indicating a potential 20.65% upside. Other analysts have varied ratings, with a consensus target price of $1,109.24. Eli Lilly's stock rose 1.3% to $994.61, with a market cap of $940.29 billion. The company reported strong quarterly earnings, beating estimates, and has set FY 2025 guidance at 23.000-23.700 EPS. Institutional investors have adjusted their stakes in the company.
Market Beat·